Introduction {#sec1-1744806918824250}
============

Various tumor types including breast, prostate, and lung carcinomas preferentially metastasize to the skeleton, where they induce significant bone remodeling, destruction, and bone cancer pain (BCP).^[@bibr1-1744806918824250][@bibr2-1744806918824250]--[@bibr3-1744806918824250]^ BCP is often severe and intractable and is a significant contributing factor to morbidity and loss of quality of life.^[@bibr4-1744806918824250]^ Most of the current pharmacological treatments provide nonselective relief for pain syndromes. Even for palliative radiotherapy, the rate of complete pain relief remains low.^[@bibr5-1744806918824250]^ Therefore, it is pivotal to investigate the pathogenesis of BCP and identify novel therapeutic targets for translational medicine.

Inflammatory, neuropathic, and/or ischemic components have been reported to be involved in cancer-induced bone pain.^[@bibr6-1744806918824250]^ In rodent BCP models, bone metastasis of cancers alters the structure, physiology, and biochemistry of the bone and concurrently induces mechanical and inflammatory hyperalgesia.^[@bibr7-1744806918824250]^ In particular, hyperexcitability of nociceptive dorsal root ganglion (DRG) neurons is associated with inflammatory pain in rodent models.^[@bibr8-1744806918824250]^ Emerging evidence indicates that alterations in gene expression^[@bibr9-1744806918824250][@bibr10-1744806918824250][@bibr11-1744806918824250][@bibr12-1744806918824250][@bibr13-1744806918824250][@bibr14-1744806918824250]--[@bibr15-1744806918824250]^ and signaling pathways^[@bibr16-1744806918824250][@bibr17-1744806918824250]--[@bibr18-1744806918824250]^ contribute to induction and maintenance of BCP. For example, upregulation of P2X3 receptors,^[@bibr9-1744806918824250]^ sodium channels Nav1.8^13^ and Nav1.9,^[@bibr10-1744806918824250]^ brain-derived neurotrophic factor,^[@bibr11-1744806918824250],[@bibr19-1744806918824250]^ acid-sensing ion channel 3,^[@bibr12-1744806918824250]^ protease-activated receptor 2 and 4,^[@bibr14-1744806918824250]^ and activation of cAMP-PKA,^[@bibr16-1744806918824250]^ PI3K/Akt,^[@bibr17-1744806918824250]^ and Hedgehog signaling^[@bibr18-1744806918824250]^ were involved in DRG-mediated BCP in a rat model. Moreover, several studies have shown attenuation of BCP in rats. These studies included overexpression of suppressor of cytokine signaling 3 in DRG,^[@bibr15-1744806918824250]^ suppression of asparaginyl endopeptidase in cancer cells, intrathecal injection of genetically engineered human bone marrow stem cells expressing the proenkephalin gene,^[@bibr20-1744806918824250]^ and intraperitoneal administration of a somatostatin receptor type 4 selective agonist, J-2156. However, comprehensive gene expression profiling of DRGs in a BCP model has not been reported. Such profiling could help identify novel therapeutic targets for the relief of BCP.

In this study, next-generation RNA-sequencing (RNA-seq) was performed to detect the differentially expressed genes (DEGs) in DRGs from a rat BCP model. The results showed that DEGs were enriched in signaling pathways associated with bone pain, inflammation, and degeneration. In particular, *Bmp2* was significantly increased in DRG neurons in a BCP rat model, and targeting of *Bmp2* by siRNA ameliorated BCP in vivo, suggesting that *Bmp2* may be an attractive therapeutic target for BCP.

Materials and methods {#sec2-1744806918824250}
=====================

Animal husbandry {#sec3-1744806918824250}
----------------

Female Sprague-Dawley rats (200 g--250 g, B&K Universal Group Limited) were used for this study. Animals were housed in separate cages at a temperature of 24 ± 1°C under a 12-h/12-h light-dark cycle and had free access to food and water. All animal procedures were carried out in accordance with the guidelines of the International Association for the Study of Pain^[@bibr21-1744806918824250]^ and were approved by the Animal Care and Use Committee of Shanghai Chest Hospital, Shanghai Jiao Tong University (Permission No. KS (Y)1616).

BCP model {#sec4-1744806918824250}
---------

The BCP model was established as previously described.^[@bibr22-1744806918824250]^ Briefly, three female Sprague-Dawley rats weighing 70 g to 80 g received an intraperitoneal inoculation of Walker 256 cells. After one week, cells in the ascites were collected and resuspended in saline to a final concentration of 2 × 10^7^ cells/mL. Then, female Sprague-Dawley rats weighing 200 g to 250 g were anesthetized with chloral hydrate (300 mg/kg, i.p.). A 23-gauge needle was inserted into the intramedullary canal of the left tibia, in the lower one third, to create a cavity for the injection of the cells, and 10 μL vehicle (sham group) or Walker 256 cells (2 × 10^5^ cells) (BCP group) were injected into the bone cavity. The cavity was sealed using bone wax prior to closure of the incision. The rats were returned to their home cages upon waking. Rats were sacrificed 21 days after tumor inoculation, and tibias were collected for gross examination.

Pain-related behaviors {#sec5-1744806918824250}
----------------------

Mechanical allodynia was determined by a significant decrease in the threshold of hind paw withdrawal to mechanical stimulation applied to the plantar surface of each hind paw.^[@bibr23-1744806918824250]^ Briefly, the animals were individually placed beneath an inverted ventilated cage with a metal-mesh floor. Von Frey monofilaments (0.6-, 1.0-, 1.4-, 2-, 4-, 6-, 8-, 10-, and 15-g), starting with 1 g and ending with 15 g in ascending order, were applied perpendicular to the plantar surface of each hind paw from beneath until the paw was withdrawn. The duration of each stimulus was approximately 2 s. Each monofilament was applied five times at 5-min intervals. Quick withdrawal or paw flinching was considered a positive response. The paw withdrawal mechanical frequency (PWMF) to each monofilament was calculated based on five applications. The paw withdrawal mechanical threshold (PWMT) was determined by the force at which PWMF ≥ 60%; 15 g was recorded as the PWMT if PWMF \< 60% to all filaments.

Movement-evoked pain was assessed by limb use score. Rats were permitted to move spontaneously on a smooth plastic table (50 cm × 50 cm). The limb use during spontaneous ambulation was scored on a scale of 4 to 0 (4. normal use; 3. slightly limping; 2. clearly limping; 1. no use of the limbs (partial); and 0. no use of the limbs (complete)).

RNA-seq {#sec6-1744806918824250}
-------

Rats were promptly sacrificed by cervical dislocation. L3-L5 DRGs were quickly harvested from sham and BCP rats (*n* = 3). Total RNA was extracted from samples using TRIzol reagent (Invitrogen, Carlsbad, CA) and the integrity verified (Agilent 2100 bioanalyzer) prior to library construction. RNA-seq was performed using the Illumina HiSeq2000 platform. Sequencing reads were first filtered for adapter sequence, low-quality sequence and rRNA. Reads were then mapped to Human Genome GRCh38 (downloaded form GENCODE) using STAR Version 2.5.2. Gene expression was quantified by RSEM Version 1.2.31 and differentially expressed transcripts (false discovery rate \< 0.05) were identified by EBSeq Version 1.10.0. Partek Genomics Suite and Gene Ontology Consortium (<http://geneontology.org>) were used for pathway and gene ontology enrichment analysis, respectively.

Western blotting {#sec7-1744806918824250}
----------------

The expression of *Bmp2* from sham and BCP mice was measured by western blot analysis. Rats were rapidly sacrificed by cervical dislocation. L3-L5 DRGs were quickly harvested and lysed; lysates were rotated for 2 h at 4°C, followed by centrifugation at 12,000 r/min for 15 min at 4°C. Supernatants were collected, and total protein concentration was titrated using a bicinchoninic acid kit. Equivalent amounts of protein (20 μg) were fractionated on 10% polyacrylamide gels. Proteins were transferred to nitrocellulose membranes (Millipore) at 100 mA for 90 min. Membranes were blocked with 5% nonfat milk in Tris-buffered saline (TBS) (50 mM Tris-HCl, 150 mM NaCl, pH 7.5) for 1 h at room temperature and incubated overnight at 4°C with primary antibody (anti-*Bmp2* at 1:1000, Abcam) in TBS containing 1% milk. Following three washes with TBST, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (1:500, Abcam) in TBS containing 1% milk for 2 h at room temperature. Immunoreactive proteins were visualized using the enhanced chemiluminescence western blotting detection system (Santa Cruz). Membranes were subsequently stripped and reprobed for anti-β-actin antibody (1: 1000, Sigma). The chemiluminescent signal from the membranes was quantified by a GeneGenome HR scanner using GeneTools software (SynGene). *Bmp2* protein expression was normalized to β-actin.

Real-time quantitative polymerase chain reaction {#sec8-1744806918824250}
------------------------------------------------

Rats were anesthetized with sodium pentobarbital (50 mg/kg i.p.), and the L3-L5 DRGs were quickly removed at the defined timepoint for each group. Total RNA was extracted using a total RNA Kit (invitrogen), and complementary DNA (cDNA) was generated using a cDNA Synthesis Kit (Promega, Madison, WI), according to the manufacturer's instructions. Real-time quantitative polymerase chain reaction (RT-qPCR) was carried out using a SYBR Green assay (Roche Ltd, Basel, Switzerland) and Rotor-Gene 3000 system (Corbett Research, Australia) based on the 2^--△△Ct^ method. β-actin was used as a housekeeping gene. The primer sequences for *Bmp2* and β-actin were as follows: *Bmp2*: Sense: 5′-AAGCCAGGTGTCTCCAAG -3′; Antisense: 5′-AAGTCCACATACAAAGGGTG-3′; β-actin: Sense: 5′-ATGGTGGTATGGGTCAGAAGG-3′; Antisense: 5′-TGGCTGGGGTGTTGAAGGTC-3′.

Immunohistochemistry {#sec9-1744806918824250}
--------------------

Animals were deeply anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and underwent sternotomy, followed by intracardiac perfusion with 200 mL saline and 200 mL 4% ice-cold paraformaldehyde in 0.1 M phosphate-buffered saline. The spinal cord and L3-L5 DRGs were removed, postfixed in 4% paraformaldehyde for 4 h, and subsequently allowed to equilibrate in 30% sucrose in phosphate-buffered saline overnight at 4°C. Immunohistochemical analyses were performed with the Histostain-SP kit (Zymed, San Francisco, CA). After rehydration, inhibition of endogenous peroxidase with 3% hydrogen peroxide, and blocking (10% rabbit serum) for 30 min, the tissue sections were incubated with a specific antibody against *Bmp2* (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) (1:500). Normal goat IgG was used as a negative control. The expression of *Bmp2* was detected by a biotin-streptavidin-peroxidase system using diaminobenzidine as a chromogen. Counterstaining was performed with hematoxylin.

Targeting *Bmp2* by siRNA in BCP model {#sec10-1744806918824250}
--------------------------------------

*Bmp2* was targeted by siRNA (sequence: Sense: 5′-GAAGCCAUCGAGGAACUUUTT-3′, Antisense: 5′-AAAGUUCCUCGAUGGCUUCTT-3′; GenePharma, Shanghai, China). Intrathecal administration of *Bmp2*-siRNA (2 μg siRNA-bone morphogenetic protein 2 (*BMP2*) or siRNA-negative control with in vivo-jet PEI (Invitrogen)) was performed seven days postinoculation of Walker 256 cells. In vivo *Bmp2* knockdown efficiency from L4-L5 DRGs was examined by RT-qPCR. PWMT and movement-evoked pain from sham and BCP rats were monitored on day 4, 6, 8, 10, and 12 postintrathecal administration.

Statistics {#sec11-1744806918824250}
----------

Data are expressed as the mean ± *SD* for behavioral and molecular assays. Statistical analyses were conducted using SPSS statistics 18.0 software and included SNK and LSD test for two-sample data and analysis of variance for multiple comparisons where appropriate. A *P* value less than 0.05 was set as the level of statistical significance. Data and figures were organized using GraphPad 5.0 software.

Results {#sec12-1744806918824250}
=======

Pain behaviors of the rat BCP model {#sec13-1744806918824250}
-----------------------------------

Rats inoculated with Walker 256 tumor cells displayed a gradual increase in sensitivity to Von Frey filament stimulation. On day 21 postinoculation of Walker 256 cancer cells, the PWMT from the BCP group decreased from the baseline level of 14.3 ± 1.4 g to 0.9 ± 0.3 g ([Figure 1(a)](#fig1-1744806918824250){ref-type="fig"}). The limb use score for the BCP group decreased from the baseline level (4.0±0.0) to 0.3 ± 0.23 ([Figure 1(b)](#fig1-1744806918824250){ref-type="fig"}). The anatomic structure of the tibia appeared thicker, and palpable tumors were noted outside the bone upon gross examination of BCP rats 21 days postinoculation of Walker 256 cancer cells ([Figure 1(c)](#fig1-1744806918824250){ref-type="fig"}).

![The establishment of BCP model by Walker 256 cancer cells inoculation in rats. Rats were inoculated with live or heat-killed Walker 256 cells as described in Materials and method section. (a) Paw withdrawal mechanical threshold (PWMT) and (b) paw withdrawal thermal latency for pain behavior test in sham and BCP group. (c) Anatomic structure of tibia bone from sham and BCP mice on 21 days postinoculation of Walker 256 cancer cells in rats. Data (a and b) are presented as mean ± *SD* (*n*=6 rats per group), and inter-group differences are assessed using Student's *t* test. \**P*\<0.05, \*\**P*\<0.01, compared with the sham control.\
BCP: bone cancer pain.](10.1177_1744806918824250-fig1){#fig1-1744806918824250}

Gene expression profiling of DRG neurons from BCP rats by RNA-seq {#sec14-1744806918824250}
-----------------------------------------------------------------

RNA-seq of rat DRG neurons was performed after confirming the BCP phenotype by radiographic imaging and pain-related behavior measurement at day 21 postinoculation of Walker 256 cancer cells. Eighty DEGs (fold change (FC) \> 1.5; false discovery rate \< 0.05) were identified in the BCP group (*n* = 3) compared to the sham group (45 upregulated and 35 downregulated). In silico functional analysis showed that 9 of these genes were associated with bone pain and 11 were associated with cancer development ([Table 1](#table1-1744806918824250){ref-type="table"} and Supplementary Table 1). Gene ontology analysis showed that the DEGs were enriched in Golgi cisternae membrane and synaptic cleft (cellular component), SMAD binding and protein kinase C binding (molecular function), BMP signaling pathway, and cartilage condensation (biological process) ([Figure 2(a)](#fig2-1744806918824250){ref-type="fig"}). Kyoto Encyclopedia of Genes and Genomes analysis indicated that the Hippo, mTOR, and transforming growth factor (TGF)-β signaling pathways were activated, while steroid biosynthesis, vitamin digestion and absorption, and histidine metabolism were suppressed in DRG from the BCP group compared to the sham group ([Figure 2(b) and (c)](#fig2-1744806918824250){ref-type="fig"}). In particular, *Bmp2* (FC = 2.09), BmP15 (FC = 2.99), and Bmpr1b (FC = 0.64) from the TGF-β superfamily were significantly increased in the BCP group.

![GO and KEGG analysis of DEGs in DRGs (BCP vs. Sham). (a) Gene ontology showed the enrichment of DEGs (BCP vs. Sham) in cellular component, molecular function, and biological process. (b) and (c) KEGG pathway analysis of DEGs (BCP vs. Sham).\
GO: gene ontology.](10.1177_1744806918824250-fig2){#fig2-1744806918824250}

###### 

Differentially expressed genes (false discovery rate \< 0.05) in DRG neurons (BCP vs. Sham) by RNA-seq.

![](10.1177_1744806918824250-table1)

  AccID        Description                                                          **Role in pain** and *cancer*                                                                                                                                                                                                         Fold change   *P*        Expression
  ------------ -------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------- ---------- ------------
  Prss12       Neurotrypsin                                                         Unknown                                                                                                                                                                                                                               0.65817       1.47E-11   Down
  Asphd2       Aspartate beta-hydroxylase domain-containing protein 2               Unknown                                                                                                                                                                                                                               0.644274      5.51E-09   Down
  Clnk         cytokine-dependent hematopoietic cell linker                         Unknown                                                                                                                                                                                                                               5.108594      1.1E-08    Up
  Sdpr         Serum deprivation-response protein                                   **Increased in peripheral inflammatory pain**,^[@bibr1-1744806918824250]^*inhibit breast cancer progression*.^[@bibr2-1744806918824250],[@bibr3-1744806918824250]^                                                                    1.515262      2.89E-07   Up
  Krt2         Keratin, type II cytoskeletal 2 epidermal                            Unknown                                                                                                                                                                                                                               0.459607      2.95E-07   Down
  Heph         Hephaestin                                                           **Play a role in migraine pathogenesis.** ^[@bibr4-1744806918824250],[@bibr5-1744806918824250]^                                                                                                                                       1.692449      3.55E-07   Up
  LOC685048    similar to paired immunoglobin-like type 2 receptor beta             Unknown                                                                                                                                                                                                                               3.77884       7.93E-07   Up
  Cd300le      Cd300 molecule-like family member E                                  unknown                                                                                                                                                                                                                               1.946738      1.42E-06   Up
  Arpc5l       Actin-related protein 2/3 complex subunit 5-like protein             *Play a role in breast cancer induced nociceptor aberrant growth* ^6^                                                                                                                                                                 1.519523      1.78E-06   Up
  Adarb2       Double-stranded RNA-specific editase B2                              Unknown                                                                                                                                                                                                                               0.441258      3.6E-06    Down
  Dpysl5       Dihydropyrimidinase-related protein 5                                Unknown                                                                                                                                                                                                                               0.62157       5.99E-06   Down
  LOC304396    Protein LOC304396                                                    Unknown                                                                                                                                                                                                                               0.662713      7.2E-06    Down
  Phldb3       Protein Phldb3                                                       *Support cancer growth via a negative feedback loop involving p53* ^7^                                                                                                                                                                1.973821      8.39E-06   Up
  Kcnj13       Inward rectifier potassium channel 13                                Unknown                                                                                                                                                                                                                               1.914467      2.52E-05   Up
  Trim14       Trim14 protein                                                       Unknown                                                                                                                                                                                                                               2.198957      3.48E-05   Up
  Arpc5l-ps1   actin related protein 2/3 complex, subunit 5-like, pseudogene 1      *Play a role in breast cancer induced nociceptor aberrant growth* ^8^                                                                                                                                                                 0.16867       3.62E-05   Down
  Ccdc17       coiled-coil domain containing 17                                     Unknown                                                                                                                                                                                                                               1.66459       5.05E-05   Up
  Ms4a6c       Protein Ms4a6c                                                       Unknown                                                                                                                                                                                                                               3.541317      6.78E-05   Up
  Slc25a34     Solute carrier family 25 member 34                                   Unknown                                                                                                                                                                                                                               2.206727      8.09E-05   Up
  Ttr          Transthyretin                                                        **Transthyretin mutation induced familial amyloid polyneuropathy ongoing refractory neuropathic pain** ^9,[@bibr10-1744806918824250]^                                                                                                 7.784136      8.44E-05   Up
  Cldn16       Claudin-16                                                           Unknown                                                                                                                                                                                                                               2.682996      8.46E-05   Up
  Cubn         Cubilin                                                              Unknown                                                                                                                                                                                                                               1.83827       9.16E-05   Up
  Lmx1a        Protein Lmx1a                                                        Unknown                                                                                                                                                                                                                               0.560506      9.72E-05   Down
  Bmp15        Protein Bmp15                                                        Unknown                                                                                                                                                                                                                               2.999657      9.87E-05   Up
  Neto1        Similar to Neuropilin-and tolloid-like protein 1 (Predicted)         Unknown                                                                                                                                                                                                                               0.559382      9.94E-05   Down
  Alpk2        Protein Alpk2                                                        Unknown                                                                                                                                                                                                                               1.650776      0.000106   Up
  Fam179a      family with sequence similarity 179, member A                        Unknown                                                                                                                                                                                                                               1.995452      0.000108   Up
  Casq2        Calsequestrin-2                                                      Unknown                                                                                                                                                                                                                               1.927822      0.000113   Up
  Aldh1b1      RCG55098                                                             **Aldehyde dehydrogenase-2 regulates nociception in rodent models of acute inflammatory pain.** ^[@bibr11-1744806918824250]^                                                                                                          0.643453      0.000121   Down
  Pmel         Silver homolog (Mouse) (Predicted), isoform CRA_a                    Unknown                                                                                                                                                                                                                               0.517713      0.000138   Down
  Bmpr1b       Receptor protein serine/threonine kinase                             **BMP signaling regulates nociceptive sensitization** ^12--14^                                                                                                                                                                        0.640617      0.000154   Down
  Hmgn5        High mobility group nucleosome-binding domain-containing protein 5   Unknown                                                                                                                                                                                                                               0.383264      0.000181   Down
  Depdc1       Protein Depdc1                                                       *DEPDC1 promotes tumorprostate cancer growth.* ^[@bibr15-1744806918824250],[@bibr16-1744806918824250]^                                                                                                                                3.357028      0.000203   Up
  Cyp2r1       Uncharacterized protein                                              Unknown                                                                                                                                                                                                                               1.606352      0.000204   Up
  Fam43a       family with sequence similarity 43, member A                         Unknown                                                                                                                                                                                                                               1.931784      0.000238   Up
  Irs1         Insulin receptor substrate 1                                         **IRS-1 plays important role in mTORC1 inhibition induces pain.** ^[@bibr17-1744806918824250]^                                                                                                                                        0.601025      0.000332   Down
  B4galnt3     Protein B4galnt3                                                     *B4galnt3 modulates the development of colon cancer, epithelial ovarian cancer, thyroid carcinoma, and neuroblastoma.* ^[@bibr18-1744806918824250][@bibr19-1744806918824250][@bibr20-1744806918824250]--[@bibr21-1744806918824250]^   0.4967        0.000337   Down
  Fut4         Alpha-(1,3)-fucosyltransferase 4                                     *FUT4 as an effective biomarker for the diagnosis of breast cancer.*                                                                                                                                                                  1.530915      0.000351   Up
  Capsl        Protein Capsl                                                        Unknown                                                                                                                                                                                                                               4.464927      0.00041    Up
  Has2         Hyaluronan synthase 2                                                Unknown                                                                                                                                                                                                                               0.577088      0.000422   Down
  Fut10        Alpha-(1,3)-fucosyltransferase 10                                    *FUT4 as an effective biomarker for the diagnosis of breast cancer.* ^[@bibr22-1744806918824250]^                                                                                                                                     0.615564      0.000423   Down
  Rad21l1      Protein Rad21l1                                                      Unknown                                                                                                                                                                                                                               1.617961      0.000423   Up
  Sytl4        Synaptotagmin-like 4, isoform CRA_b                                  Unknown                                                                                                                                                                                                                               1.840074      0.000426   Up
  Mpv17l2      Similar to FKSG24 (Predicted), isoform CRA_b                         Unknown                                                                                                                                                                                                                               1.528021      0.000459   Up
  Bmp2         Bone morphogenetic protein 2                                         **Bone morphogenetic protein-2-mediated pain and inflammation in a rat model of posterolateral arthrodesis.** ^[@bibr23-1744806918824250]^                                                                                            2.043089      0.000466   Up
  Slc6a11      Sodium- and chloride-dependent GABA transporter 3                    Unknown                                                                                                                                                                                                                               0.491062      0.000489   Down
  Ddit4        DNA damage-inducible transcript 4 protein                            *DDIT4 plays roles ofgastric cancer and proliferation.* ^[@bibr24-1744806918824250],[@bibr25-1744806918824250]^                                                                                                                       1.695812      0.00053    Up
  Dab2         Disabled homolog 2                                                   *Dab2 is required for migration and invasion of prostate cancer.* ^[@bibr26-1744806918824250]^                                                                                                                                        1.550524      0.000539   Up
  LMCD1        LIM and cysteine-rich domains 1                                      *LMCD1 mutations promoted cell migration and tumor metastasis in hepatocellular carcinoma.* ^[@bibr27-1744806918824250]^                                                                                                              2.180509      0.000542   Up
  Slc10a6      Solute carrier family 10 member 6                                    Unknown                                                                                                                                                                                                                               3.655645      0.00059    Up
  CTGF         CTGF protein                                                         **Expression of CTGF increases in painful disc fibrosis and degeneration.** ^[@bibr28-1744806918824250],[@bibr29-1744806918824250]^                                                                                                   3.048432      0.00062    Up
  Arntl        Aryl hydrocarbon receptor nuclear translocator-like, isoform CRA_d   Unknown                                                                                                                                                                                                                               1.689748      0.00064    Up
  Rsph1        Radial spoke head 1 homolog (Chlamydomonas)                          Unknown                                                                                                                                                                                                                               0.63951       0.00065    Down
  Clca4l       chloride channel calcium activated 4-like                            Unknown                                                                                                                                                                                                                               0.115282      0.000733   Down
  Rhox5        Homeobox protein Rhox5                                               Unknown                                                                                                                                                                                                                               4.463283      0.000766   Up
  Ccl24        Protein Ccl24                                                        Unknown                                                                                                                                                                                                                               0.348753      0.000835   Down

Note: The references cited in this table are shown in Supplementary Table 1.

Upregulation of *Bmp2* in DRG is associated with BCP {#sec15-1744806918824250}
----------------------------------------------------

*Bmp2*, similarly to other BMP family members, plays an important role in the development of bone and cartilage. Consistent with the RNA-seq data, upregulation of *Bmp2* in BCP rats was further validated by immunohistochemistry ([Figure 3(a)](#fig3-1744806918824250){ref-type="fig"}), RT-qPCR ([Figure 3(b)](#fig3-1744806918824250){ref-type="fig"}), ELISA ([Figure 3(c)](#fig3-1744806918824250){ref-type="fig"}), and western blotting ([Figure 3(d)](#fig3-1744806918824250){ref-type="fig"}).

![Upregulation of the expression of Bmp2 in DRGs of BCP rats. The expression of Bmp2 in DRGs from BCP rats was validated by immunohistochemistry (a), RT-qPCR (b), ELISA (c), and western blotting (d). Immunofluorescent microscopy was done using anti-BMP2 antibody as described in Materials and method section. The mRNA level of BMP2 was measured by real-time RT-PCR and normalized by β-actin. The protein level of BMP2 in DRG samples was measured by ELISA and western blotting signals. Representative protein bands are presented on the top of the responding histogram. Data (b and c) are presented as mean ± *SD* (*n*=12 rats per group), and inter-group differences are assessed using Student's *t* test. \**P*\<0.05, \*\**P*\<0.01, compared with the sham control.\
BCP: bone cancer pain; BMP2: bone morphogenetic protein 2.](10.1177_1744806918824250-fig3){#fig3-1744806918824250}

Targeting *Bmp2* ameliorates BCP in vivo {#sec16-1744806918824250}
----------------------------------------

Information arising from RNA-seq data and subsequent validation prompted us to further investigate the role of *Bmp2* upregulation during BCP hypersensitivity. *Bmp2* was targeted by siRNAs in BCP rats. Targeting by siRNA resulted in significantly reduced *Bmp2* transcription ([Figure 4(a)](#fig4-1744806918824250){ref-type="fig"}) and ameliorated BCP in rats as indicated by increased PWMT levels ([Figure 4(b)](#fig4-1744806918824250){ref-type="fig"}) at day 4, 6, 8, 10, and 12 postintrathecal siRNA administration. Consistently, limb use scores were also increased in BCP rats at day 6, 8, and 10 postintrathecal *Bmp2*-siRNA administration ([Figure 4(c)](#fig4-1744806918824250){ref-type="fig"}). These data indicated that *Bmp2* antagonists may be effective for BCP treatment in vivo.

![Targeting Bmp2 by intrathecal siRNA administration in BCP rats. (a) The knockdown effect of Bmp2 siRNA was tested by RT-qPCR (*n*=8). (b) and (c) PWMT and PWTL were measured after Bmp2 siRNA administration in BCP rats at different time points. Data (b and c) are presented as mean ± *SD* (*n*=12 rats per group), and inter-group differences are assessed using Student's *t* test. \**P*\<0.05, \*\**P*\<0.01, compared with the BCP+NC-siRNA group.\
BCP: bone cancer pain; BMP2: bone morphogenetic protein 2.](10.1177_1744806918824250-fig4){#fig4-1744806918824250}

Discussion {#sec17-1744806918824250}
==========

Primary and metastatic cancers that affect the bone are frequently associated with severe and intractable BCP including nociceptive, neuropathic, and inflammatory pain.^[@bibr1-1744806918824250],[@bibr24-1744806918824250]^ Although the etiology of BCP remains unclear, animal models of BCP make it possible to unravel neuropathological processes that occur in the region of tumor growth. In recent years, next-generation sequencing including RNA-seq has been used to analyze the cellular transcriptome for mechanistic study and translational medicine. However, gene expression profiling by RNA-seq of DRGs during BCP and peripheral hypersensitivity has not been reported. Here, we made use of RNA-seq and identified eighty DEGs in DRGs from BCP compared to sham rats. Functional annotation showed that nine of the DEGs were associated with bone pain. For example, *Ttr* mutation was associated with familial amyloid polyneuropathy and refractory neuropathic pain.^[@bibr25-1744806918824250],[@bibr26-1744806918824250]^ Sdpr was reported to be increased in peripheral inflammatory pain.^[@bibr27-1744806918824250]^ In addition, eleven DEGs were associated with cancer development, suggesting that the alterations in these genes may play important roles in cancer metastasis. Gene ontology and Kyoto Encyclopedia of Genes and Genomes analysis showed that the DEGs were enriched in the Hippo, mTOR, and TGF-β signaling pathways and associated with inflammation, enzyme activity, synaptic cleft, etc. In previous studies of BCP,^[@bibr28-1744806918824250]^ dorsal horn activation of mTOR was shown to participate in N-methyl-D-aspartate receptor-triggered dorsal central sensitization. In addition, previous studies^[@bibr29-1744806918824250]^ have found that TGF-β1 is highly expressed in tumor-bearing bone, where it contributes to BCP via the upregulation and sensitization of transient receptor potential vanilloid type 1 in primary sensory neurons.

BMPs are a group of growth and morphogenetic factors originally discovered by their ability to induce the formation of bone and cartilage. Among the BMP family members, BMP2-7 belongs to the TGF-β superfamily of proteins. BMP2, 4, 6, and 7 are commonly referred to as the osteogenic BMPs, based on their potent bone-inducing activity.^[@bibr30-1744806918824250]^ BMP3 is a negative regulator of bone density.^[@bibr31-1744806918824250]^ BMP4 is an important factor in early nervous system development and regeneration after injury and a critical mediator of adult physiological plasticity.^[@bibr32-1744806918824250]^ In this study, we found that *Bmp2* was significantly increased in DRGs from a rat BCP model. Notably, *Bmp2* is involved in the Hedgehog and TGF-β signaling pathways and in cytokine-cytokine receptor interactions important for cell proliferation, adhesion, migration, and apoptosis. BMP targeting, either through deletion of BMP coreceptor RGMb or BMP antagonist Noggin, retarded early axonal regeneration after sciatic nerve crush injury.^[@bibr33-1744806918824250]^ Moreover, implantation of recombinant human BMP2 in lumbar spine triggered potent neuroinflammatory responses in the DRGs.^[@bibr34-1744806918824250]^ However, the role of *Bmp2* in DRGs during peripheral hypersensitivity of BCP was unknown.

There are several limitations for the current study. First, we did not include double labeling of the nociceptive neurons and *Bmp2* in the immunohistochemical analyses. Therefore, it is unknown whether *Bmp2* is specifically expressed in nociceptive DRG neurons. Second, our assessment of siRNA efficiency by mRNA expression analysis would be improved by further confirmation using western blot analysis.

Despite their limitations, our results confirm the importance of *Bmp2* in the mechanism of peripheral sensitization of BCP. In this study, breast cancer cell injection led to upregulation of *Bmp2* expression in DRG neurons, which was correlated with enhanced neuronal excitability and pain hypersensitivity. In vivo targeting of *Bmp2* by siRNA attenuated pain hypersensitivity and ameliorated BCP in rats. Our data suggest that BMP2 antagonists may be effective for treatment of BCP hypersensitivity.
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